BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Feb 13, 2021
Product Development

Howdy partner: MD Anderson’s evolving industry collaboration strategy

The shifting balance between oncology candidates and patients available for trials, and the rise of complex modalities, is shaping the way MD Anderson builds partnerships and develops new assets. University of Texas MD Anderson Cancer...
BioCentury | Feb 13, 2021
Product Development

Feb. 12 Quick Takes: G1’s first approval is first in class; plus Seagen, Denali, Roche and Takeda

Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) rose 20% to $37.15 in after-hours trading after FDA approved Cosela trilaciclib to decrease bone marrow suppression caused by chemotherapy in adults being treated for extensive-stage small cell lung cancer....
BioCentury | Feb 9, 2021
Product Development

KalVista gains on Phase II data for oral HAE treatment

KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its oral on-demand protease inhibitor for HAE attacks met its primary endpoint of reducing the use of rescue medication.  The Phase II trial was a randomized,...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

SomaLogic tops off recent series AProteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total to $214 million. New investors in the second close...
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

It’s been a busy year for Genentech’s business development team as the company adds discovery and early clinical development deals. The latest deal — a partnership with Relay on a SHP2 inhibitor ...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and other genetic epilepsies. The Cambridge, Mass.-based start-up, which has...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
Items per page:
1 - 10 of 2542